×
About 7,768 results

ALLMedicine Angioedema Center

Research & Reviews  3,203 results

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks.
https://doi.org/10.1111/all.14416
Allergy Riedl MA, Maurer M et. al.

May 25th, 2020 - Lanadelumab demonstrated efficacy in preventing HAE attacks in the phase 3 HELP Study. To assess time to onset of effect and long-term efficacy of lanadelumab, based on exploratory findings from the HELP Study. Eligible patients with HAE type I/II...

Long-term Safety and Efficacy of Subcutaneous C1-Inhibitor in Older Patients With Hered...
https://doi.org/10.1016/j.anai.2020.05.015
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology; Bernstein JA, Schwartz L et. al.

May 23rd, 2020 - Patients ≥65 years old with hereditary angioedema (HAE) due to C1-inhibitor (C1-INH) deficiency may have an altered response to treatment and be at higher risk for treatment-related adverse events (AEs) due to comorbidities and polypharmacy. Inves...

Novel homozygous variants in the SERPING1 gene in two Turkish families with hereditary ...
https://doi.org/10.1111/imcb.12362
Immunology and Cell Biology; Mete Gökmen N, Rodríguez-Alcalde C et. al.

May 22nd, 2020 - Hereditary angioedema due to deficiency of the C1-inhibitor (HAE-C1INH; MIM#106100) is a rare autosomal disorder and affected individuals are generally heterozygous for dominant negative variants in the SERPING1 gene. Homozygosity for SERPING1 pat...

Angioedema in COVID-19.
https://doi.org/10.1093/eurheartj/ehaa452
European Heart Journal; Cohen AJ, DiFrancesco MF et. al.

May 21st, 2020 - Angioedema in COVID-19.|2020|Cohen AJ,DiFrancesco MF,Solomon SD,Vaduganathan M,|

Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.
https://doi.org/10.1007/s12016-020-08794-6
Clinical Reviews in Allergy & Immunology; Metz M, Vadasz Z et. al.

May 17th, 2020 - Chronic spontaneous urticaria (CSU) is defined as the spontaneous development of itchy hives and/or angioedema due to known or unknown causes that last for at least 6 weeks. At any given time, CSU is believed to affect 0.5-1% of the global populat...

see more →

Guidelines  17 results

The international WAO/EAACI guideline for the management of hereditary angioedema-The 2...
https://doi.org/10.1111/all.13384
Allergy Maurer M, Magerl M et. al.

Jan 10th, 2018 - Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. I...

BSACI guideline for the management of chronic urticaria and angioedema.
https://doi.org/10.1111/cea.12494
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology; Powell RJ, Leech SC et. al.

Feb 25th, 2015 - This guidance for the management of patients with chronic urticaria and angioedema has been prepared by the Standards of Care Committee of the British Society for Allergy and Clinical Immunology (BSACI). The guideline is based on evidence as well ...

The diagnosis and management of acute and chronic urticaria: 2014 update
https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20and%20Parameters/Urticaria-2014.pdf
Bernstein, J.

Apr 30th, 2014 - Theworkgroup was formed by the JTFPP to develop a practiceparameter to address the diagnosis and treatment of urticaria withor without angioedema. The chair, Jonathan Bernstein, MD,invited workgroup members to participate in the parameterdevelopme.

A consensus parameter for the evaluation and management of angioedema in the emergency ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100605
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine; Moellman JJ, Bernstein JA et. al.

Apr 15th, 2014 - Despite its relatively common occurrence and life-threatening potential, the management of angioedema in the emergency department (ED) is lacking in terms of a structured approach. It is paramount to distinguish the different etiologies of angioed...

A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, an...
https://doi.org/10.1016/j.jaci.2013.03.034
The Journal of Allergy and Clinical Immunology; Zuraw BL, Bernstein JA et. al.

Jun 3rd, 2013 - These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council ...

see more →

Drugs  391 results see all →

Clinicaltrials.gov  3,833 results

Promethegan - promethazine hydrochloride suppository-PD-Rx Pharmaceuticals, Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b72dcf9-a4a1-4cc1-b7c2-a0bc2740fe97

May 27th, 2020 - Promethazine HCl Suppositories, USP are useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioe...

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks.
https://doi.org/10.1111/all.14416
Allergy Riedl MA, Maurer M et. al.

May 25th, 2020 - Lanadelumab demonstrated efficacy in preventing HAE attacks in the phase 3 HELP Study. To assess time to onset of effect and long-term efficacy of lanadelumab, based on exploratory findings from the HELP Study. Eligible patients with HAE type I/II...

Long-term Safety and Efficacy of Subcutaneous C1-Inhibitor in Older Patients With Hered...
https://doi.org/10.1016/j.anai.2020.05.015
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology; Bernstein JA, Schwartz L et. al.

May 23rd, 2020 - Patients ≥65 years old with hereditary angioedema (HAE) due to C1-inhibitor (C1-INH) deficiency may have an altered response to treatment and be at higher risk for treatment-related adverse events (AEs) due to comorbidities and polypharmacy. Inves...

Novel homozygous variants in the SERPING1 gene in two Turkish families with hereditary ...
https://doi.org/10.1111/imcb.12362
Immunology and Cell Biology; Mete Gökmen N, Rodríguez-Alcalde C et. al.

May 22nd, 2020 - Hereditary angioedema due to deficiency of the C1-inhibitor (HAE-C1INH; MIM#106100) is a rare autosomal disorder and affected individuals are generally heterozygous for dominant negative variants in the SERPING1 gene. Homozygosity for SERPING1 pat...

Angioedema in COVID-19.
https://doi.org/10.1093/eurheartj/ehaa452
European Heart Journal; Cohen AJ, DiFrancesco MF et. al.

May 21st, 2020 - Angioedema in COVID-19.|2020|Cohen AJ,DiFrancesco MF,Solomon SD,Vaduganathan M,|

see more →

News  315 results

Recurrent Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema Refractory to Fresh Frozen Plasma
https://www.mdedge.com/fedprac/article/213630/hospital-medicine/recurrent-angiotensin-converting-enzyme-inhibitor-induced/page/0/1?channel=327

Dec 5th, 2019 - Discussion The standard therapy for ACEI-inducedangioedema continues to be airway management and discontinuation of medication. However, life-threatening progression of symptoms have led to the use of off-label therapies, including FFP and bradyki.

FDA Drug Approvals: Pediatrics — Year in Review 2018
https://www.medscape.com/viewarticle/907375

Jan 14th, 2019 - New Antimicrobials New tetracyclines and antimicrobials for influenza, malaria, onchocerciasis, smallpox, and more New Drugs for Seizures Stiripentol and cannabidiol approved for seizures associated with Lennox-Gastaut syndrome or Dravet syndrome ...

HAE Attacks Cut With Lanadelumab
https://www.medpagetoday.com/rheumatology/generalrheumatology/76622

Nov 30th, 2018 - Action Points Patients with type I or type II hereditary angioedema (HAE) suffer from regular, unpredictable and life-disrupting attacks, and patients are in need of better drugs to control this lifelong disabling condition. Patients whose HAE is ...

Lanadelumab Prevents Hereditary Angioedema Attacks
https://www.medscape.com/viewarticle/905625

Nov 28th, 2018 - NEW YORK (Reuters Health) - Treatment with lanadelumab significantly reduced attacks of hereditary angioedema (HAE) type I and II in the phase 3 randomized controlled HELP study, supporting its use as a prophylactic therapy for HAE, researchers sa...

Trial Data Back Lanadelumab for HAE Prevention
https://www.medpagetoday.com/rheumatology/generalrheumatology/76542

Nov 27th, 2018 - Prophylactic treatment with lanadelumab (Takhzyro) prevented hereditary angioedema attacks and led to a clinically-meaningful impact on quality of life, according to the pivotal HELP trial that led to recent FDA approval. The monoclonal antibody c...

see more →

Patient Education  9 results see all →